Study links ibuprofen CVD risks
This article was originally published in The Tan Sheet
Executive Summary
Ibuprofen, among other nonselective nonsteroidal anti-inflammatory drugs, might increase the risk of cardiovascular disease events in certain patients, according to research in the August issue of Arthritis Care & Research. Working with consumers at least 80 years old who take NSAIDs to relieve arthritis symptoms, the researchers from Brigham and Women's Hospital in Boston find "several patient characteristics identify important subgroups that may be at an increased risk when using specific agents," according to the study. The researchers link ibuprofen use with increased CVD event risk in patients with histories of hypertension, prior myocardial infarction, rheumatoid arthritis and chronic renal disease
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.